Skip to content

Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)

Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00574184
Acronym
PANPI
Enrollment
10
Registered
2007-12-17
Start date
2005-08-31
Completion date
2008-03-31
Last updated
2017-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Keywords

ED, Erectile Dysfunction

Brief summary

The specific aim of this pilot study is to describe the angiographic prevalence and pattern of internal pudendal artery (and associated inflow vessel) atherosclerosis in patients with erectile dysfunction who are non-responsive to PDE-5 inhibitors (i.e., Viagra) who are referred for clinically-indicated cardiac catheterization.

Detailed description

The specific aim of this study is to determine if the deep penile arteries can be seen angiographically from the iliac arteries to delineate penile vasculature. Significant obstructive atherosclerotic disease of the deep penile arteries may be present in impotent males. The etiology of erectile dysfunction is multifactorial and may involve vascular disease, endocrine disorders, neurologic disease, prescription medications, psychological issues and/or trauma in any given patient. Vascular disease in patients with erectile dysfunction may be due to trauma, congenital anomalies, or atherosclerosis.

Interventions

None listed

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male patients * at least 50 years * erectile dysfunction * dissatisfaction with their use of a phosphodiesterase-5 inhibitor * coronary artery disease (or at risk for coronary artery disease) * undergoing diagnostic cardiac catheterization or patients with peripheral vascular disease undergoing peripheral arteriography

Exclusion criteria

* Patients who respond favorably to phosphodiesterase-5 inhibitors * known non-vascular etiologies of their erectile dysfunction * probable neurogenic erectile dysfunction due to radiation injury, surgery, or transurethral resection of the prostate * calculated GFR \< 60 ml/min/1.73 m2 will also be excluded * disease that necessitates complex percutaneous intervention will be excluded per the investigators discretion

Design outcomes

Primary

MeasureTime frame
Distal aortography with iliofemoral run-off will be performed to evaluate disease in the common and internal iliac arteries.During Procedural Cath

Secondary

MeasureTime frame
Selective angiography of the internal pudendal artery (and accessory pudendal artery if present) will be performed bilaterally.During Procedural Cath
Intra-arterial nitroglycerin (or papaverine or tolazoline if nitroglycerin is contraindicated) will be used to facilitate angiographic visualization of the internal pudendal and penile arteries.During Procedural Cath

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026